Anti-Human IGF-BP5
| Code | Size | Price |
|---|
| LEI-I-384-25ug | 25 ug | £375.00 |
Quantity:
| LEI-I-384-100ug | 100 ug | £682.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Caprine (Goat)
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Shipping:
Ambient
Storage:
The lyophilized antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for twelve months from date of receipt. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.
Further Information
Conjugate/Tag/Label:
Antigen Affinity Purified
Format:
This antigen affinity purified polyclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.3 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.
Formulation:
This antigen affinity purified polyclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.3 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.
Immunogen:
NS0-Derived Recombinant Human IGFBP-5
Long Description:
Insulin-like growth factor binding protein 5, also known as IGFBP5 is a member of the insulin-like growth factor binding protein (IGFBP) family that are cysteine-rich proteins that act as a carrier protein. It is expressed highly in the kidney. IGFBP-5 has an autonomous role in the regulation of cell fate in development and in tumourigenesis.1
NCBI Gene:
3488
Target:
IGF-BP5
References
1. Pell, JM. et al. (2004) J of Cell Science 117:1737
Related Products
| Product Name | Product Code | Supplier | Anti-Human IGF-BP5 - Biotin | LEI-I-385 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|